Blue Spots and Red Flags

Distinguishing Congenital Dermal Melanocytosis from bruising in infants

What Exactly Is Congenital Dermal Melanocytosis?

Congenital Dermal Melanocytosis (CDM), historically termed Mongolian blue spots, is a benign congenital pigmentary condition characterised by blue-grey patches most commonly found over the lumbosacral region, buttocks, and shoulders.

These marks frequently prompt concern among clinicians unfamiliar with their appearance, particularly in skin of colour; however, CDM is almost always a normal variant rather than a bruise or injury.

Although overwhelmingly benign, CDM has been reported in rare association with metabolic disorders such as GM1 gangliosidosis, Hunter syndrome, and Niemann–Pick disease. As Gupta and Thappa (2013) note in their review of Mongolian Blue spots, these links are uncommon but clinically relevant, reinforcing the need for accurate identification and an appreciation of broader medical contexts.

Understanding CDM properly requires a brief return to foetal development. Melanocytes originate in the neural crest, a transient embryonic structure that also gives rise to peripheral nerves, components of the autonomic nervous system, and parts of the craniofacial skeleton. Between approximately 10–14 weeks of gestation, melanocyte precursors leave the neural crest and migrate through the dermis toward the dermo-epidermal junction, where they settle in the basal epidermis and contribute to normal skin pigmentation.

In CDM, some of these migrating cells do not reach their intended destination and instead remain “trapped” within the deeper dermis. Their persistence at this level produces the characteristic blue-grey patches seen at birth. This explanation is widely taught in dermatology, yet, as highlighted by Gautam and Shingala in 2023, it rests on a small number of histological studies conducted several decades ago.

Despite CDM being one of the most common pigmentary findings in newborns worldwide, there appears to be remarkably little contemporary work validating, refining, or challenging this mechanism. As a result, several clinically relevant questions remain unanswered.

It is not yet clear why certain melanocyte precursors fail to complete their upwards migration, whether “entrapment” reflects a true developmental error or a normal variant in melanocyte biology, or what genetic, molecular, or microenvironmental factors may influence this process. Likewise, the mechanisms underlying the variation in lesion size, distribution, and spontaneous fading remain poorly understood. Modern developmental biology has made substantial progress in understanding neural crest behaviour, yet these advances have rarely been applied to CDM.

Why Does CDM Look Blue? The Tyndall Effect

Although CDM develops from pigment rather than trauma, its colour can make it appear deceptively bruise-like. The explanation lies not in pathology but in physics. When melanin is located unusually deep in the dermis, incoming light is scattered by collagen and other dermal structures; shorter blue wavelengths are reflected toward the observer, while longer wavelengths travel deeper and are absorbed. This is an optical phenomenon known as the Tyndall effect, which is the same mechanism responsible for the blue appearance of deep tattoos and even the sky.

The melanocytes themselves are not blue as once thought; they appear blue only because of their position and the way light is reflected from them. Recognising this helps clinicians understand why CDM can mimic bruising so convincingly, particularly in infants with melanin-rich skin, where the contrast can be visually striking. Without this appreciation of optics, static and benign pigmentation may be misinterpreted as evidence of harm.

Prevalence, Terminology, and the Evidence Gap

CDM prevalence varies significantly by ethnicity. This bar chart, based on a literature review conducted in the 1980s, illustrates that CDM is far from rare. It appears to be widespread across many populations and is a routine neonatal finding.

Although these figures offer one of the broadest comparisons across ethnic groups, they are nearly 50 years old and may not fully reflect contemporary, increasingly diverse populations. However, they underscore the ongoing issue that despite the widespread prevalence of CDM, efforts to update or expand the available datasets have been minimal.

This paradox is echoed by Gautam and Shingala’s review (2023), which notes that although CDM is among the most common pigmentary findings in newborns worldwide, its underlying biology and epidemiology continue to rely on a narrow and outdated evidence base. Modern developmental research is scarce, and current prevalence studies are often geographically or ethnically specific, limiting their generalisability. Furthermore, a recent observational neonatal study from Maharashtra, India, found CDM (Mongolian spots) in 81.6% of 500 newborns, predominantly in the sacral region.

While valuable, such findings reflect a relatively homogenous population and cannot be extrapolated to settings such as the UK, where infant demographics vary widely. Terminology inconsistencies further complicate interpretation: studies variously label lesions as “Mongolian spots,” “Dermal Melanocytosis,” or “CDM,” each with differing inclusion criteria and classification systems.

The result is a fragmented epidemiological landscape and one that does not align with the frequency with which clinicians encounter CDM in practice. Despite being a near-universal finding in some populations, CDM remains under-researched, inconsistently reported, and poorly represented in modern data, leaving clinicians without a clear understanding of its true global prevalence.

Distinguishing Blue from Bruise

Despite its benign nature, CDM routinely poses a challenge for safeguarding assessments because it can closely mimic bruising. This difficulty is greatest for clinicians with limited exposure to skin of colour or insufficient dermatological training, both of which have been repeatedly shown to influence diagnostic confidence.

Distinguishing CDM from bruising is central to safe infant safeguarding, yet it remains one of the most challenging frontline assessments. CDM’s blue-grey appearance and soft borders can resemble a bruise, particularly to clinicians with limited exposure to skin of colour, and this uncertainty may lead to escalation before the lesion is correctly identified.

A clear understanding of how bruises behave helps anchor the distinction. Traumatic bruising reflects vascular injury, with blood escaping into soft tissues before undergoing a predictable metabolic breakdown.

As haemoglobin is processed by macrophages, bruises evolve through recognisable colour stages—from red-purple to blue, green, yellow, and eventual resolution. These colour transitions, however, may appear differently on melanin-rich skin: bruises may appear deeper, subtler, or more as warmth, swelling, or textural change than dramatic discolouration. High-quality clinical resources such as Skin Deep (Don’t Forget the Bubbles) are therefore invaluable for clinicians developing confidence in recognising bruising across diverse skin tones.

CDM behaves differently in ways that are diagnostically useful. Because the pigment lies deep in the dermis and is not linked to vascular trauma, CDM lesions are entirely static (6). Their appearance does not change over days or weeks, and their texture and temperature remain normal. This lack of evolution, rather than colour alone, is often the most reliable clinical marker for distinguishing CDM from bruising.

Distribution provides further clinical guidance on distinguishing between bruising and CDM. Kettner et al. (2020) described a three-type classification (sacral, extra-sacral, and combined) based on a forensic cohort study, highlighting that benign Dermal Melanocytosis can appear in locations where clinicians may feel less confident. However, the framework has clear limitations. This tool lacks external validation and offers no data on diagnostic accuracy or generalisability. As it has yet to be incorporated into dermatology or safeguarding guidance, it is therefore best understood as descriptive rather than diagnostic.

A wider issue underpins these challenges: there is no validated national tool to assist clinicians in differentiating CDM from bruising. No structured scoring systems, diagnostic algorithms, or population-level accuracy studies exist, resulting in frontline assessment relying heavily on clinical reasoning.

In practice, this means attending closely to the fundamentals: CDM is present at birth or early infancy, remains stable, and is non-tender; bruises are acquired lesions that evolve, may be painful or swollen, and typically correspond to a plausible mechanism of injury. When uncertainty persists, detailed documentation, including adequate lighting, a precise written description, and photographs with parental consent, serves as a crucial safeguard for both clinicians and families.

Ultimately, reliable differentiation protects infants on both sides of the safeguarding equation. It ensures that genuine injuries are appropriately recognised while preventing benign pigmentation from prompting unnecessary investigations, distress, or unwarranted suspicion. Accurate identification of CDM is therefore not simply a dermatological skill; it is a core component of equitable, culturally competent safeguarding practice.

Red Flags – but not as you know them…

Although CDM itself is benign, the context in which it appears, our terminology, evidence base, and safeguarding processes all raise red flags in clinical practice.

Our first flag is linguistic. The historical term Mongolian blue spot, still commonly encountered in clinical notes and older textbooks, originates from 19th-century racial classification systems. Its continued use can cause discomfort for families, reinforce a sense of “otherness,” and contribute to uncertainty among clinicians more familiar with modern terminology. Language in medicine is never neutral; it shapes perception, frames clinical judgement, and influences clinicians’ confidence in their observations.

Next is our evidence gap. Despite CDM affecting a high proportion of infants in many ethnic groups, there is no national reporting system, no prevalence registry or robust dataset exploring rates of misdiagnosis or its consequences. Most publications simply note that CDM “may mimic bruising” without assessing the frequency with which this confusion occurs in real-world safeguarding settings. The absence of standardised or widely validated diagnostic tools means that clinicians must rely on their own experience, which is inevitably shaped by the diversity of the population they serve and the training they have received. This variability can create structural vulnerability within safeguarding assessments.

These gaps have real-world implications. Case reports and forensic reviews describe infants who underwent comprehensive safeguarding investigations, including skeletal surveys, neuroimaging, ophthalmology assessments, and social care involvement, before CDM was recognised. In one widely cited case, a three-year-old girl was institutionalised and separated from her parents for several days after her CDM was mistaken for bruises. The error was avoidable; the impact was profound. Although such cases may appear anecdotal, they highlight how diagnostic uncertainty disproportionately affects families of colour, particularly in systems where training in skin-of-colour presentations is limited.

This brings us to the final red flag: Inequality. CDM is far more common in infants with melanin-rich skin, yet dermatology teaching materials and safeguarding exemplars still overwhelmingly feature white skin. This mismatch can heighten the risk of misinterpretation, thereby increasing referrals, family distress, and longer-term mistrust of healthcare services. For some parents, an initial child-protection enquiry, even one later resolved, reshapes their relationship with healthcare for years.

Misdiagnosis of CDM is therefore not simply a clinical issue. It is a matter of health inequality, cultural safety, and systemic responsibility.

A Structured Clinical Approach

In the absence of a universally validated tool and given these red flags, clinicians can rely on the following four core elements to support clear differentiation between CDM and bruising.

History

CDM is present from birth or very early infancy, whereas bruises are acquired. Establishing accurate timing with caregivers and checking neonatal or health visitor records often provides the most decisive distinction (21).

Behaviour

CDM is static: it does not change colour, size, temperature, or tenderness over time. Bruises evolve predictably as blood products break down and may be painful, swollen, or associated with petechiae. Focusing on temporal behaviour, rather than colour alone, is especially important in melanin-rich skin.

Distribution

CDM is usually lumbosacral, though extra-sacral sites are recognised. Bruises typically correlate with a plausible mechanism of injury and are more often found over bony prominences or soft tissue. Distribution should be weighed alongside history and behaviour, not interpreted in isolation.

Documentation

Accurate, contemporaneous documentation, including clear descriptions, appropriate lighting, and photographs with consent, supports safe decision-making and protects both families and clinicians when cases progress through safeguarding pathways.

Blue Spots, Red Flags and the Space Between

CDM is an extremely common and overwhelmingly benign pigmentary variant, yet its resemblance to bruising, paired with its outdated and racialised terminology, limited exposure to skin-of-colour presentations, and a fragmented evidence base, creates an environment where misinterpretation is possible. When this happens, the consequences extend far beyond dermatology: they reach into safeguarding pathways, family wellbeing, and trust in healthcare.

Recognising CDM accurately is therefore not merely a matter of diagnostic precision; it is an act of safeguarding, cultural humility, and health equality. Until research provides clearer guidance or more robust tools, clinicians must rely on careful history, pattern recognition, and thoughtful documentation to navigate this complex space.

While advocating for clearer recognition of CDM, it is essential to emphasise that this does not diminish the importance of safeguarding. Sometimes a bruise is simply a bruise, and vigilance in identifying non-accidental injury remains critical to protecting children from harm.

However, equitable safeguarding also requires awareness of how misdiagnosis disproportionately affects marginalised families, particularly when dermatology resources and training materials underrepresent melanin-rich skin. The aim is not to undermine safeguarding processes, but to highlight where structural gaps risk unintended consequences and to ensure that all infants, regardless of skin tone, are assessed through a lens of accuracy, cultural humility, and fairness.

The distinction between a benign blue spot and a safeguarding red flag lies not in the lesion itself, but in the clinical lens through which it is viewed.

References

1. Gupta D, Thappa DM. Mongolian spots: How important are they? World J Clin Cases. 2013 Nov 16;1(8):230-2. doi: 10.12998/wjcc.v1.i8.230. PMID: 24340274; PMCID: PMC3856299.
2. Lumbosacral dermal melanocytosis [Internet]. DermNet NZ. [cited 2025 Dec 2]. Available from: https://dermnetnz.org/topics/lumbosacral-dermal-melanocytosis
3. British Association of Dermatologists. Congenital dermal melanocytosis. Patient Information Leaflet (PIL). June 2024 [updated June 2024; cited 2025 Dec 4]. Available from: https://www.bad.org.uk/pils/congenital-dermal-melanocytosis/
4. Richey PM, Norton SA. John Tyndall’s Effect on Dermatology. JAMA Dermatol. 2017;153(3):308. doi:10.1001/jamadermatol.2016.0505
   2008;25(2):233–5. doi:10.1111/j.1525-1470.2008.00641.x.
5. Cordova A. The Mongolian spot: a study of ethnic differences and a literature review. Clin Pediatr (Phila). 1981 Nov;20(11):714-9. doi: 10.1177/000992288102001105. PMID: 7028354.
6. Gautam M, Shingala K. A review of dermal melanocytosis. Indian J Paediatric Dermatol. 2023;24(3):211–216. doi:10.4103/ijpd.ijpd_66_22.
7. Quazi S, Choudhary S, Singh AL, Saoji V, Khan K, Jawade S. The study on the prevalence of Mongolian spots in the neonates. J Family Med Prim Care. 2023 Jul;12(7):1435-1438. doi: 10.4103/jfmpc.jfmpc_2326_22. Epub 2023 Jul 14. PMID: 37649743; PMCID: PMC10465051.
8. Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr. 2012;161(2):240–5. doi:10.1016/j.jpeds.2012.02.052.
9. Prasad T, Tully J. Late onset congenital dermal melanocytosis – ‘Mongolian blue spots’ confused as child abuse: are there more lessons to be learnt? J Paediatr Child Health. 2017;53(9):908-11. doi:10.1111/jpc.13608.
10. AlJasser M, Al-Khenaizan S. Cutaneous mimickers of child abuse: a primer for pediatricians. Eur J Pediatr. 2008;167(11):1221-30. doi:10.1007/s00431-008-0792-0.
11. Child Protection Companion [Internet]. Royal College of Paediatrics and Child Health (RCPCH); [cited 2025 Dec 2]. Available from: https://childprotection.rcpch.ac.uk/child-protection-companion/ Congenital dermal melanocytosis [Internet]. British Association of Dermatologists; [cited 2025 Dec 2]. Available from: https://bad.org.uk/pils/congenital-dermal-melanocytosis
12. Wang S-H. What makes bruises change color over time? The Scientist. 2023 Jun 1 [cited 2025 Dec 04]. Available from: https://www.the-scientist.com/what-makes-bruises-change-color-over-time-73383
13. Thavarajah D, Vanezis P, Perrett D. Assessment of bruise age on dark-skinned individuals using tristimulus colorimetry. Med Sci Law. 2012 Jan;52(1):6-11. doi: 10.1258/msl.2011.011038. Epub 2011 Sep 29. PMID: 22041123.
14. Dermal melanocytosis [Internet]. Skin Deep – Don’t Forget The Bubbles. [cited 2025 Dec 2]. Available from: https://dftbskindeep.com/all-diagnoses/dermal-melanocytosis/
15. Kettner M, Birngruber CG, Niess C, Baz-Bartels M, Bunzel L, Verhoff MA, Lux C, Ramsthaler F. Mongolian spots as a finding in forensic examinations of possible child abuse: implications for case work. Int J Legal Med. 2020;134(3):1141-8. doi:10.1007/s00414-019-02208-9.
16. Zhong CS, Huang JT, Nambudiri VE. Revisiting the history of the “Mongolian spot”: The background and implications of a medical term used today. Pediatr Dermatol. 2019 Sep;36(5):755-757. doi: 10.1111/pde.13858. Epub 2019 May 29. PMID: 31141213.
17. Yale S, Tekiner H, Yale ES. Reimagining the Terms Mongolian Spot and Sign. Cureus. 2021 Dec 13;13(12):e20396. doi: 10.7759/cureus.20396. PMID: 35036226; PMCID: PMC8752411.
18. Christoffersen S. A three-year-old girl was removed from her parents because of failure to recognize Mongolian spots. Scand J Forensic Sci. 2016;22(1):3–5. doi:10.1515/sjfs-2016-0002.
19. Lester JC, Taylor SC, Chren MM. Under-representation of skin of colour in dermatology images: not just an educational issue. Br J Dermatol. 2019 Jun;180(6):1521-1522. doi: 10.1111/bjd.17608. PMID: 31157429.
20. The Primary Care Dermatology Society. Congenital dermal melanocytosis (syn. Mongolian spots). Clinical guidance. May 28 2022 [cited 2025 Dec 4]. Available from: https://www.pcds.org.uk/clinical-guidance/mongolian-spot
21. Kemp AM, Maguire SA, Nuttall D, Collins P, Dunstan F. Bruising in children who are assessed for suspected physical abuse. Arch Dis Child. 2014 Feb;99(2):108-13. doi: 10.1136/archdischild-2013-304339. Epub 2013 Sep 16. PMID: 24043551; PMCID: PMC3913107.